Transcode Therapeutics (RNAZ) Non Operating Interest Expenses (2020 - 2025)

Transcode Therapeutics (RNAZ) has reported Non Operating Interest Expenses for 5 consecutive years, with $542.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Non Operating Interest Expenses fell 70.41% year-over-year to $542.0; the trailing twelve-month figure through Dec 2025 stood at $6616.0 (down 75.32% YoY), and the FY2025 full-year result was $6616.0, down 75.33% from the prior year.
• Non Operating Interest Expenses eased to $542.0 in Q4 2025 per RNAZ's latest filing, from $5960.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $52770.0 in Q1 2021 and bottomed at $114.0 in Q1 2025.
• Historically, Non Operating Interest Expenses has averaged $13171.1 across 4 years, with a median of $8774.5 in 2023.
• The widest YoY moves for Non Operating Interest Expenses: up 17.72% in 2021, down 99.88% in 2021.
• Over 4 years, Non Operating Interest Expenses stood at $333.0 in 2021, then jumped by 5108.71% to $17345.0 in 2023, then plunged by 89.44% to $1832.0 in 2024, then plunged by 70.41% to $542.0 in 2025.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $542.0, $5960.0, and $114.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.